Article Text

Download PDFPDF
Periodic screening with prostate-specific antigen testing reduced mortality from prostate cancer

Statistics from Altmetric.com

STUDY DESIGN

Design:

randomised controlled trial (European Randomised Study of Screening for Prostate Cancer [ERSPC]). Current Controlled Trials ISRCTN49127736.

Allocation:

not concealed, at least in part.* In 3 countries, randomisation occurred before consent was obtained; in the other 4 countries, only consenting participants were randomised, but allocation concealment was unclear.

Blinding:

blinded (outcome adjudication committees).*

STUDY QUESTION

Setting:

7 European countries.

Participants:

162 243 men 55–69 years of age (mean age 61 y). Some countries also enrolled …

View Full Text

Footnotes

  • *See glossary.

    Abstract and commentary also appear in ACP Journal Club.

  • Source of funding: Europe Against Cancer; Fifth and Sixth Framework Program of the European Union; Beckman Coulter; local agencies and health authorities in participating countries.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.